OrthoPediatrics Corp.

As of September 30, 2026, OrthoPediatrics Corp. carries a market capitalization of 581.58M, placing it among publicly traded companies globally. Its enterprise value stands at 635.72M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

OrthoPediatrics Corp.'s next confirmed earnings release is scheduled for March 10, 2027.

As of September 30, 2026, OrthoPediatrics Corp. has 26.12M shares outstanding.

These figures are as of September 30, 2026. The price-to-sales ratio is 2.01, and the price-to-book ratio stands at 1.71.

These figures are as of September 30, 2026. The EV/Sales ratio of 2.41 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 635.72M versus a market cap of 581.58M, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2026, OrthoPediatrics Corp. maintains a current ratio of 4.55, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 28.99, indicating elevated leverage, while an interest coverage ratio of -0.30 demonstrates limited ability to service its debt obligations.

Over the twelve months ended September 30, 2026, OrthoPediatrics Corp. posted a negative return on equity (ROE) of -9.84, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.76, reflecting losses generated across the asset base. The company generates approximately 438,764.12 in revenue per employee across its workforce of 602.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.51 indicates how many times OrthoPediatrics Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2026, OrthoPediatrics Corp. recorded 294,000.00 in income tax expense. The company reported a pretax loss of -33.59M and -33.88M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on November 6, 2026, OrthoPediatrics Corp.'s stock has gained approximately 93.66% over the past 52 weeks. The 50-day moving average sits at 24.06, while the 200-day moving average is 19.89.

Over the twelve months ended September 30, 2026, OrthoPediatrics Corp. generated 264.14M in revenue and converted that into -33.88M in net income, yielding earnings per share of -1.42. EBITDA reached -2.15M, while operating income came in at -21.52M.

As of September 30, 2026, OrthoPediatrics Corp. holds 44.23M in cash and equivalents against 98.36M in total debt, resulting in a net debt position of 81.22M. Total book value stands at 339.35M, with working capital of 197.61M providing operational flexibility.

OrthoPediatrics Corp. produced 12.50M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -9.31M in capital expenditures, free cash flow totaled 3.18M - equivalent to 0.13 per share.

Over the twelve months ended September 30, 2026, OrthoPediatrics Corp. posted a gross margin of 73.76, reflecting its pricing power and cost economics. The operating margin of -8.15 and net profit margin of -12.83 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 0.60, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.57, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to OrthoPediatrics Corp. shareholders.

As of September 30, 2026, OrthoPediatrics Corp. has an Altman Z-Score of 2.09, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.